Pfizer’s JAK1 inhibitor Cibinqo approved in US to treat atopic dermatitis

By NS Healthcare Staff Writer

17 Jan 22

Cibinqo is an oral, once-daily, oral small molecule that selectively inhibits Janus kinase 1 (JAK1), to modulate multiple…

PharmaceuticalsRegulation

Gilead withdraws cancer drug Zydelig to treat NHL and SLL

By NS Healthcare Staff Writer

17 Jan 22

Zydelig will be continued as a treatment for CLL and FL in the European Union (EU), the UK,…

PharmaceuticalsRegulation

Novavax’ protein-based Covid-19 vaccine approved in South Korea

By NS Healthcare Staff Writer

13 Jan 22

Nuvaxovid, Novavax’ recombinant, adjuvanted Covid-19 vaccine, is the first protein-based Covid-19 shot to get regulatory approval in South…

PharmaceuticalsRegulation

Pfizer unveils positive results for Prevnar 20, Comirnaty booster coadministration

By NS Healthcare Staff Writer

13 Jan 22

In the Phase 3 study, PREVNAR 20 vaccine triggered similar responses for all 20 serotypes, either with Pfizer-BioNTech…

PharmaceuticalsClinical trials

Vertex’s KAFTRIO + ivacaftor wins EU nod for cystic fibrosis treatment in children

By NS Healthcare Staff Writer

12 Jan 22

The oral medicine has been approved for the treatment of cystic fibrosis in young patients aged six to…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Pfizer partners with Beam to develop rare disease therapies

By NS Healthcare Staff Writer

11 Jan 22

Under the four-year research collaboration, the companies will focus on in vivo base editing programmes for three targets…

PharmaceuticalsBiotechnology Equipment and Materials

Acadia, Stoke to develop RNA-based treatments for neurodevelopmental diseases

By NS Healthcare Staff Writer

11 Jan 22

The collaboration is expected to allow Stoke to receive potential milestone payments of up to $907m

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Sanofi partners with Exscientia to develop up to 15 new drug candidates

By NS Healthcare Staff Writer

10 Jan 22

Under the new agreement, the two firms will detect and select target projects using Exscientia’s personalised medicine platform…

PharmaceuticalsPartnerships and Licensing Agreements

Merck to acquire biopharma CDMO Exelead for $780m

By NS Healthcare Staff Writer

07 Jan 22

The acquisition of Exelead, a full-service contract development and manufacturing organisation focused on Lipid Nanoparticle formulations, is expected…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Lilly partners with Entos to develop therapies for neurologic diseases

By NS Healthcare Staff Writer

07 Jan 22

The collaboration will use Entos’ Fusogenix nucleic acid delivery technology and Lilly's therapeutic cargo to develop nucleic acid…

PharmaceuticalsPartnerships and Licensing Agreements